Previewing the Plenary Sessions at AUA 2023

The scheduled Plenary Sessions at the 2023 American Urological Association (AUA) Annual Meeting are full of lectures and discussion relevant to genitourinary oncologists.

On Friday, attendees will be thrown right into the fire with an early-morning “Crossfire: Controversies in Urology” session on the multidisciplinary management of clinical N1 prostate cancer. A host of speakers, including Christopher Evans, MD, of the UC Davis School of Medicine, will take part in the discussion. Throughout the morning, attendees can expect to hear panel discussions on triplet therapy for newly diagnosed metastatic hormone-sensitive prostate cancer, management of small renal masses, and new AUA guidelines on the early detection of prostate cancer, among other topics. Additionally, a “State-of-the-Art” Lecture will compare and contrast different treatment pathways and options for histologic subtypes of renal cell carcinoma.

The afternoon will feature similarly diverse sessions, including a debate on transrectal versus transperineal biopsy for detecting prostate cancer, new AUA guidelines on upper tract urothelial carcinoma, and the impact of prostate-specific membrane antigen positron emission tomography on treatment decision-making. Another “Crossfire: Controversies in Urology” session will pull in differing opinions on thermal ablation versus partial nephrectomy for a 3-cm renal mass in a 49-year-old male, and a “Second Opinion Cases” panel led by Angela Smith, MD, MS, of the University of North Carolina at Chapel Hill, will touch on bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.

On Saturday morning, all eyes will be on Neal Shore, MD, FACS, of the Carolina Urologic Research Center, as he presents the results of the EMBARK trial, a phase 3, randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer.

On Sunday morning, Sevann Helo, MD, of the Mayo Clinic, and multiple other speakers will share the stage to discuss sexuality after prostate cancer treatment.

The final day of the conference will feature a few vitally important sessions, including a presentation on the controversies related to robotic kidney transplant and the all-encompassing “Take Home Messages” for kidney, bladder, and prostate cancer.